Drug interactions between Linzess and Movantik
Interactions between your drugs
There were no interactions found in our database between Linzess and Movantik - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.
- Linzess is in the drug class guanylate cyclase-C agonists.
- Linzess is used to treat the following conditions:
- Movantik is a member of the drug class peripheral opioid receptor antagonists.
- Movantik is used to treat the following conditions:
Drug and food interactions
Applies to: Movantik (naloxegol)
Do not consume grapefruit or grapefruit juice during treatment with naloxegol. Grapefruit juice can significantly increase the blood levels of naloxegol. You may be more likely to experience side effects and withdrawal symptoms such as sweating, tearing, runny nose, chills, diarrhea, abdominal pain, anxiety, insomnia, irritability, restlessness, and yawning. Taking naloxegol with food can also increase its absorption into the blood stream. Therefore, you should take it on an empty stomach at least 1 hour before or 2 hours after a meal. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Applies to: Linzess (linaclotide)
Taking linaclotide with food may increase gastrointestinal side effects such as diarrhea, abdominal pain, and gas. The absorption of any other oral medication you may take can be affected if you develop frequent or severe diarrhea. To reduce the risk of gastrointestinal intolerance, linaclotide should be taken on an empty stomach at least 30 minutes prior to the first meal of the day. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.